Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - peginterferon beta-1a - sklerosi multipla - immunostimulanti, - kura ta 'sklerożi multipla li tirkadi ta' ripetizzjoni f'pazjenti adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - solriamfetol hydrochloride - narcolepsy; sleep apnea, obstructive - psychoanaleptics, - sunosi huwa indikat biex itejbu wakefulness u jnaqqas nagħas eċċessiv bi nhar f'pazjenti adulti b'narkolessija (ma ' jew mingħajr l-kataplessja). sunosi huwa indikat biex itejbu wakefulness u jnaqqas nagħas eċċessiv bi nhar (eds) f'pazjenti adulti bil-apnea waqt l-irqad (osa) li eds ma ġewx trattati b'mod sodisfaċenti mill primarja osa-terapija, bħal kontinwu pożittiva-passaġġ tan-nifs ta ' pressjoni (cpap).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - influwenza, bniedem - vaċċini - profilassi tal-influwenza fl-anzjani (65 sena u aktar). fluad tetra għandu jintuża skond ir-rakkomandazzjonijiet uffiċjali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

insmed netherlands b.v. - amikacin sulfate - infezzjonijiet ta 'trap respiratorji - antibatteriċi għal użu sistemiku, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - drogi oħra tas-sistema nervuża - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bluebird bio (netherlands) b.v. - elivaldogene autotemcel - adrenoleukodystrophy - drogi oħra tas-sistema nervuża - treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age, with an abcd1 genetic mutation, and for whom a human leukocyte antigen (hla) matched sibling haematopoietic stem cell donor is not available.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - tumur stromali gastrointestinali - aġenti antineoplastiċi - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.